Scientists have identified key molecules that mediate radioresistance in glioblastoma multiforme; these molecules are a potential target for the treatment of this brain cancer.
Glioblastoma multiforme (GBM), is the most aggressive type of brain cancer. It is treated by radiation therapy combined with chemotherapy. However, even with treatment, the five-year survival rate for GBM is less than 7%. One of the major causes for this is that GBM rapidly develops radioresistance (resistance to radiotherapy) by unknown mechanisms.
A team of scientists from Hokkaido University and Stanford University have revealed a mechanism by which GBM develops radioresistance.
